HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Penederm

This article was originally published in The Rose Sheet

Executive Summary

Penederm: Foster City, CA-based firm posts third quarter revenues of $802,000, down 24.1% from the same period a year ago. The company reported a net loss of $1.7 mil. compared to a 1994 third quarter loss of $1.3 mil. According to the firm, the loss "reflect[s] expenses associated with two large human clinical trials...designed to strengthen marketing claims" for the firm's retinoic acid acne products and its KP363 antifungal cream treatments. Penederm has been addressing outstanding clinical issues concerning the retinoic acid products since receiving an "unapprovable" letter for its NDAs from FDA this spring ("The Rose Sheet" Aug. 28, In Brief). During the third quarter, the firm filed marketing approval applications for the acne products in the European Union...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel